Phase Genomics helps scientists solve today’s most pressing health and environmental challenges. Thousands of researchers throughout the world apply Phase Genomics’ ultra-long-range genome sequencing technology and computational tools to drive new innovations and therapeutic discoveries across human health, agriculture, infectious disease, and beyond. • CytoTerra™ – Based on Genetic Proximity Mapping™ (GPM), it enables a comprehensive survey of the genomic landscape and new insights in oncology and genetic disease research. • Proximo® – High-resolution chromosome-scale genome assembly for plants, animals, humans, fungi and microbes. • ProxiMeta™ – Advanced metagenomic and viral discovery powered by proximity-ligation sequencing. Founded in 2015 by genome scientists, engineers, and entrepreneurs, our mission is to empower scientists with industry-leading genomic tools that accelerate breakthrough discoveries. The company serves academic and industry researchers in diverse fields and industries throughout the US and globally through our network of distribution partners. Learn more: phasegenomics.com
Looking for a particular Phase Genomics employee's phone or email?
The Phase Genomics annual revenue was $6 million in 2026.
Ivan Liachko is the Co-founder and CEO of Phase Genomics.
9 people are employed at Phase Genomics.
Phase Genomics is based in Seattle, Washington.
The NAICS codes for Phase Genomics are [541, 5417, 54, 54171, 541713].
The SIC codes for Phase Genomics are [87, 873].